Toni M. Brand, Ph.D. - Publications

Affiliations: 
2014 Cellular & Molecular Pathology University of Wisconsin, Madison, Madison, WI 
Area:
Cell Biology, Oncology, Pharmacology

25 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Brand TM, Iida M, Dunn EF, Luthar N, Kostopoulos KT, Corrigan KL, Wleklinski MJ, Yang D, Wisinski KB, Salgia R, Wheeler DL. Correction: Nuclear Epidermal Growth Factor Receptor Is a Functional Molecular Target in Triple-negative Breast Cancer. Molecular Cancer Therapeutics. 18: 868. PMID 30936412 DOI: 10.1158/1535-7163.MCT-18-1183  0.92
2018 Iida M, Brand TM, Campbell DA, Li C, Wheeler DL. Correction: Yes and Lyn play a role in nuclear translocation of the epidermal growth factor receptor. Oncogene. PMID 30518873 DOI: 10.1038/S41388-018-0572-X  0.92
2018 Brand TM, Iida M, Stein AP, Corrigan KL, Braverman CM, Coan JP, Pearson HE, Bahrar H, Fowler TL, Bednarz BP, Saha S, Yang D, Gill PS, Lingen MW, Saloura V, et al. Correction: AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 24: 6099. PMID 30510088 DOI: 10.1158/1078-0432.Ccr-18-3194  0.92
2018 Brand TM, Iida M, Luthar N, Starr MM, Huppert EJ, Wheeler DL. Corrigendum to: "Nuclear EGFR as a molecular target in cancer" [Radiother Oncol 108 (2013) 370-77]. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. PMID 30442378 DOI: 10.1016/J.Radonc.2018.10.011  0.92
2017 Brand TM, Iida M, Corrigan KL, Braverman CM, Coan JP, Flanigan BG, Stein AP, Salgia R, Rolff J, Kimple RJ, Wheeler DL. The receptor tyrosine kinase AXL mediates nuclear translocation of the epidermal growth factor receptor. Science Signaling. 10. PMID 28049763 DOI: 10.1126/Scisignal.Aag1064  0.92
2016 Iida M, Bahrar H, Brand TM, Pearson HE, Coan JP, Orbuch RA, Flanigan BG, Swick AD, Prabakaran P, Lantto J, Horak ID, Kragh M, Salgia R, Kimple RJ, Wheeler DL. Targeting the HER family with Pan-HER effectively overcomes resistance to cetuximab. Molecular Cancer Therapeutics. PMID 27422810 DOI: 10.1016/S0959-8049(16)32810-6  0.92
2016 Rodems TS, Iida M, Brand TM, Pearson HE, Orbuch RA, Flanigan BG, Wheeler DL. Adaptive responses to antibody based therapy. Seminars in Cell & Developmental Biology. 50: 153-63. PMID 26808665 DOI: 10.1016/J.Semcdb.2016.01.001  0.92
2015 Brand TM, Iida M, Stein AP, Corrigan KL, Braverman CM, Coan JP, Pearson HE, Bahrar H, Fowler TL, Bednarz BP, Saha S, Yang D, Gill PS, Lingen MW, Saloura V, et al. AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 2601-12. PMID 25767293 DOI: 10.1158/1078-0432.Ccr-14-2648  0.92
2014 Iida M, Brand TM, Starr MM, Huppert EJ, Luthar N, Bahrar H, Coan JP, Pearson HE, Salgia R, Wheeler DL. Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy. Molecular Cancer. 13: 242. PMID 25344208 DOI: 10.1186/1476-4598-13-242  0.92
2014 Brand TM, Iida M, Stein AP, Corrigan KL, Braverman CM, Luthar N, Toulany M, Gill PS, Salgia R, Kimple RJ, Wheeler DL. AXL mediates resistance to cetuximab therapy. Cancer Research. 74: 5152-64. PMID 25136066 DOI: 10.1158/0008-5472.Can-14-0294  0.92
2014 Brand TM, Iida M, Dunn EF, Luthar N, Kostopoulos KT, Corrigan KL, Wleklinski MJ, Yang D, Wisinski KB, Salgia R, Wheeler DL. Nuclear epidermal growth factor receptor is a functional molecular target in triple-negative breast cancer. Molecular Cancer Therapeutics. 13: 1356-68. PMID 24634415 DOI: 10.1158/1535-7163.Mct-13-1021  0.92
2014 Rolle CE, Kanteti R, Surati M, Nandi S, Dhanasingh I, Yala S, Tretiakova M, Arif Q, Hembrough T, Brand TM, Wheeler DL, Husain AN, Vokes EE, Bharti A, Salgia R. Combined MET inhibition and topoisomerase I inhibition block cell growth of small cell lung cancer. Molecular Cancer Therapeutics. 13: 576-84. PMID 24327519 DOI: 10.1158/1535-7163.Mct-13-0109  0.92
2013 Iida M, Brand TM, Starr MM, Li C, Huppert EJ, Luthar N, Pedersen MW, Horak ID, Kragh M, Wheeler DL. Sym004, a novel EGFR antibody mixture, can overcome acquired resistance to cetuximab. Neoplasia (New York, N.Y.). 15: 1196-206. PMID 24204198 DOI: 10.1593/Neo.131584  0.92
2013 Li C, Brand TM, Iida M, Huang S, Armstrong EA, van der Kogel A, Wheeler DL. Human epidermal growth factor receptor 3 (HER3) blockade with U3-1287/AMG888 enhances the efficacy of radiation therapy in lung and head and neck carcinoma. Discovery Medicine. 16: 79-92. PMID 23998444  0.92
2013 Brand TM, Iida M, Luthar N, Wleklinski MJ, Starr MM, Wheeler DL. Mapping C-terminal transactivation domains of the nuclear HER family receptor tyrosine kinase HER3. Plos One. 8: e71518. PMID 23951180 DOI: 10.1371/Journal.Pone.0071518  0.92
2013 Brand TM, Iida M, Luthar N, Starr MM, Huppert EJ, Wheeler DL. Nuclear EGFR as a molecular target in cancer. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. 108: 370-7. PMID 23830194 DOI: 10.1016/J.Radonc.2013.06.010  0.92
2013 Kawada I, Hasina R, Lennon FE, Bindokas VP, Usatyuk P, Tan YH, Krishnaswamy S, Arif Q, Carey G, Hseu RD, Robinson M, Tretiakova M, Brand TM, Iida M, Ferguson MK, et al. Paxillin mutations affect focal adhesions and lead to altered mitochondrial dynamics: relevance to lung cancer. Cancer Biology & Therapy. 14: 679-91. PMID 23792636 DOI: 10.4161/Cbt.25091  0.92
2013 Iida M, Brand TM, Campbell DA, Starr MM, Luthar N, Traynor AM, Wheeler DL. Targeting AKT with the allosteric AKT inhibitor MK-2206 in non-small cell lung cancer cells with acquired resistance to cetuximab. Cancer Biology & Therapy. 14: 481-91. PMID 23760490 DOI: 10.4161/Cbt.24342  0.92
2013 Traynor AM, Weigel TL, Oettel KR, Yang DT, Zhang C, Kim K, Salgia R, Iida M, Brand TM, Hoang T, Campbell TC, Hernan HR, Wheeler DL. Nuclear EGFR protein expression predicts poor survival in early stage non-small cell lung cancer. Lung Cancer (Amsterdam, Netherlands). 81: 138-41. PMID 23628526 DOI: 10.1016/J.Lungcan.2013.03.020  0.92
2013 Iida M, Brand TM, Campbell DA, Li C, Wheeler DL. Yes and Lyn play a role in nuclear translocation of the epidermal growth factor receptor. Oncogene. 32: 759-67. PMID 22430206 DOI: 10.1038/Onc.2012.90  0.92
2012 Brand TM, Wheeler DL. KRAS mutant colorectal tumors: past and present. Small Gtpases. 3: 34-9. PMID 22714415 DOI: 10.4161/Sgtp.18751  0.92
2011 Brand TM, Iida M, Li C, Wheeler DL. The nuclear epidermal growth factor receptor signaling network and its role in cancer. Discovery Medicine. 12: 419-32. PMID 22127113  0.92
2011 Brand TM, Dunn EF, Iida M, Myers RA, Kostopoulos KT, Li C, Peet CR, Wheeler DL. Erlotinib is a viable treatment for tumors with acquired resistance to cetuximab. Cancer Biology & Therapy. 12: 436-46. PMID 21725209 DOI: 10.4161/Cbt.12.5.16394  0.92
2011 Brand TM, Iida M, Wheeler DL. Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab. Cancer Biology & Therapy. 11: 777-92. PMID 21293176 DOI: 10.4161/Cbt.11.9.15050  0.92
2011 Brand TM, Wheeler DL. Treating PIK3CA and EGFR overexpressing breast cancers with lithium citrate. Cancer Biology & Therapy. 11: 368-70. PMID 21228636 DOI: 10.4161/Cbt.11.3.14696  0.92
Show low-probability matches.